Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌(包括胃食管结合部腺癌)的患者,HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。
Inova Schar Cancer Institute, Fairfax, Virginia, United States
Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos, Other, Brazil
Centro de Oncologia da Bahia, Salvador, Other, Brazil
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Hainan Qionghai People's Hospital, Qionghai, Hainan, China
The Second Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, China
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
West China Hospital, Sichuan University, Chengdu, Chengdu, Sichuan, China, China
Beijing Cancer Hospital, Beijing, Beijing, China
Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
Shandong Provincial Hospital Affiliated to Shandong First Medical Universiry, Jinan, Shandong, China
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, Shandong, China
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.